The Drug That Cleared Her Skin Is the One Drug Ruled Out for Her Spine
Her skin has never looked better on the drug she's on. Her new axial symptoms fall into the one PsA domain where that same drug class carries an explicit guideline recommendation against use — a genuine gap between what's working and what's now needed.
Carmen L. has worked as a research librarian for eleven years and, until eight months ago, thought of her psoriasis as a solved problem: guselkumab, an IL-23 inhibitor started two years ago for severe plaque disease, brought her PASI down from 22 to 1 and kept it there, clear enough that she stopped thinking about her skin day to day. The new problem started as a dull ache low in her back that she blamed on the library's aging desk chairs, until it settled into a pattern she couldn't explain that way — morning stiffness lasting nearly two hours, improving with movement rather than rest, and a positive HLA-B27 result that, combined with sacroiliitis on MRI, confirmed axial involvement as a genuine new domain of her psoriatic arthritis, distinct from the peripheral joint disease she doesn't have and the skin disease that's been so thoroughly controlled.
The complication is not that guselkumab has stopped working — her skin remains clear, and nothing about her axial symptoms suggests systemic disease escaping control generally. It's that IL-23 inhibition, effective for her skin and for peripheral joint and enthesitis domains in other patients, has a specific, negative evidence record for axial disease: the ustekinumab axSpA program was halted for futility and risankizumab likewise failed to separate from placebo in ankylosing spondylitis, a large enough and consistent enough finding that the 2026 ACR guideline update carries a strong recommendation against using IL-23 inhibitors for axial disease in either axSpA or axial PsA specifically — the one domain her new symptoms actually fall into. Continuing a drug that's doing real, measurable work for one domain while being specifically the wrong mechanism for a new domain that just appeared is not a failure of her current therapy; it's a genuine structural gap between how PsA's domains are treated as one disease day to day and how differently each domain actually responds to any single mechanism.
On exam, her spine shows reduced lateral flexion bilaterally and a positive FABER test on the right, with no synovitis in any peripheral joint and skin that remains, by her own description, "the best it's looked in a decade." She was matter-of-fact about the tension in front of the group — if a new drug means even a modest step back on her skin, she wants that named plainly in advance rather than discovered three months from now.
A drug that works, for the wrong domain now
The guideline here isn't ambiguous: IL-23 inhibitors carry a strong recommendation against use for axial disease in either axSpA or axial PsA, based on multiple trials that failed to separate from placebo. Her axial symptoms are now the dominant clinical problem. I'd switch her to a TNF or IL-17 inhibitor — both have real, positive axial-disease evidence, and both would also be expected to cover her peripheral and skin domains reasonably well as a whole-disease strategy.
I don't disagree about the axial evidence, but I want to name what "reasonably well" is actually asking her to risk: a PASI of 1, sustained for two years, is not a common outcome, and drug response is individual enough that switching mechanisms doesn't guarantee she'll get anywhere near that level of clearance again. There's no guideline basis for assuming a TNF or IL-17 inhibitor will replicate what guselkumab specifically did for her skin.
I'd rather add a second agent for her spine and keep the one drug we know, for certain, already works this well for her — not switch away from a proven individual response on the strength of a class-level guideline that says nothing about her specifically.
I understand not wanting to gamble a genuinely excellent skin outcome, but combination biologic therapy isn't a free option either — it means two agents suppressing overlapping parts of the immune system at once, with real infection risk and thin controlled safety data for this specific pairing. Given that a single TNF or IL-17 inhibitor is well-evidenced across all three of her domains, not just her spine, I'd favor a clean switch over combination therapy — but I'd choose the switch carefully: an IL-17 inhibitor has real skin efficacy in its own right, which gives her the best realistic chance of keeping something close to her current clearance while actually treating the domain that's active now.
Agreed: taper off guselkumab and start ixekizumab, with PASI and BASDAI both rechecked at 12 weeks to confirm the switch is holding on both fronts, not just the axial domain it was chosen for.
Not agreed: what to do if her skin clearance genuinely degrades on the new agent despite ixekizumab's own real psoriasis efficacy. The dermatologist would consider adding a topical or reintroducing a second agent at that point; the rheumatologist would want to confirm the axial disease is genuinely controlled first before adding anything back, given how directly that was the reason for the switch.